Core Viewpoint - Clene Inc. is actively engaging with investors at the Benchmark 14 Annual Discovery One-on-One Investor Conference, highlighting its focus on neurodegenerative disease treatments through innovative biopharmaceutical solutions [1][2]. Company Overview - Clene Inc. is a late clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and neuronal function to address neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS) [2]. - The company's investigational therapy, CNM-Au8, is designed to improve the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway while mitigating oxidative stress [2]. Conference Details - The Benchmark 14 Annual Discovery One-on-One Investor Conference is scheduled for December 4, 2025, in New York, New York, featuring 1x1 investor meetings [2].